Login / Signup

Treatment of transfusion-dependent congenital dyserythropoietic anemia Type I patients with pegylated interferon alpha-2a.

Abed Abu-QuiderMahdi AslehHanna ShalevYariv FruchtmanMeriam Ben-HaroshGuy BeckJosef Kapelushnik
Published in: European journal of haematology (2020)
Pegylated interferon α2a therapy is efficacious in CDA-I patients with a reasonable safety profile.
Keyphrases
  • dendritic cells
  • chronic kidney disease
  • immune response
  • combination therapy
  • sickle cell disease
  • cell therapy